2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
Morita A, Strober B, Burden A, Choon S, Anadkat M, Marrakchi S, Tsai T, Gordon K, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl M. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. The Lancet 2023, 402: 1541-1551. PMID: 37738999, DOI: 10.1016/s0140-6736(23)01378-8.Peer-Reviewed Original ResearchConceptsPhysician Global Assessment scoreGPP flaresGlobal assessment scoreFlare preventionDose-response relationshipPrimary endpointAssessment scoresPhase 2b trialPustular psoriasis flarePlacebo-controlled trialReceptor monoclonal antibodyEligible study participantsQuality of lifeDose-response curveSubcutaneous placeboPlacebo groupWeek 48Pustular psoriasisPrimary outcomePsoriasis flareTreatment armsPatient groupHypersensitivity reactionsPatient morbiditySpesolimab
2021
Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists
Strober B, Kotowsky N, Medeiros R, Mackey R, Harrold L, Valdecantos W, Flack M, Golembesky A, Lebwohl M. Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists. Dermatology And Therapy 2021, 11: 529-541. PMID: 33638115, PMCID: PMC8018987, DOI: 10.1007/s13555-021-00493-0.Peer-Reviewed Original ResearchGPP flaresTreatment optionsPustular psoriasis flareAvailable treatment optionsChronic autoinflammatory diseaseStandard of careUnmet medical needNeutrophilic pustulesSteroid withdrawalPustular psoriasisPsoriasis flareConsensus guidelinesEffective therapyAutoinflammatory diseasesDiagnostic criteriaCurrent unmetConclusionThis surveyMedical needNew flareNatural historyMost dermatologistsDermatologistsTreatmentPustulesLimited information
2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Strober B, Poulin Y, Kerdel F, Langley R, Gu Y, Gupta S, Okun M, Papp K. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. Journal Of The American Academy Of Dermatology 2011, 64: 671-681. PMID: 21414495, DOI: 10.1016/j.jaad.2010.03.009.Peer-Reviewed Original ResearchConceptsPhysician global assessmentSuboptimal responseSuboptimal therapyWeek 16Global assessmentPhase IIIb trialChronic plaque psoriasisOpen-label designOpen-label studyPrimary end pointPercentage of patientsNB-UVB phototherapySeverity Index scorePsoriasis clinical trialsTreatment of psoriasisDosage taperingIIIb trialPrior therapyPlaque psoriasisPsoriasis AreaPsoriasis flarePsoriasis patientsSafety profilePatient enrollmentClinical trials